Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
AELIS.PADay performance
| AELIS.PA | |
|---|---|
| Price | 13.40 |
| Change Pct | 0.00 |
| Change Abs | 0.00 |
| Market Cap | 175.9 million |
| Eps | -0.41 |
| Pe Ratio | -32.68 |
| Outstanding Shares | 13.1 million |
| Volume | 6 |
| Avg Volume | 283 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | FR |
| Announcement Earnings | 2023-09-25 18:00:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
The peer analysis is for none of your tickers available
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
Company descriptions
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.